Can Fite Biopharma (CANF) leaps on positive test results

April 27, 2015 10:30 AM | 12 seconds read |
Can Fite Biopharma Ltd (ADR) (NYSE MKT: CANF) shares rose 35.8% to $2.92 on positive results from further analysis of its Phase II/III psoriasis trial. Share volume was 114,000, more than quadruple an all-day average of 27,000
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!